19,367 Shares in Lantheus Holdings, Inc. (NASDAQ:LNTH) Purchased by B. Metzler seel. Sohn & Co. Holding AG

B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 19,367 shares of the medical equipment provider's stock, valued at approximately $2,126,000.

A number of other large investors also recently added to or reduced their stakes in LNTH. Moloney Securities Asset Management LLC purchased a new stake in shares of Lantheus during the third quarter worth $1,066,000. Hancock Whitney Corp increased its position in shares of Lantheus by 265.6% during the first quarter. Hancock Whitney Corp now owns 20,151 shares of the medical equipment provider's stock worth $1,254,000 after acquiring an additional 14,639 shares during the period. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Lantheus during the second quarter worth $290,000. Van ECK Associates Corp increased its holdings in Lantheus by 58.6% in the third quarter. Van ECK Associates Corp now owns 58,472 shares of the medical equipment provider's stock valued at $6,469,000 after buying an additional 21,604 shares during the last quarter. Finally, Swedbank AB increased its holdings in Lantheus by 21.1% in the third quarter. Swedbank AB now owns 722,243 shares of the medical equipment provider's stock valued at $79,266,000 after buying an additional 125,843 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Lantheus Trading Up 3.7 %

Shares of NASDAQ LNTH traded up $3.20 during midday trading on Friday, reaching $90.52. 2,014,903 shares of the company were exchanged, compared to its average volume of 1,020,692. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $126.89. The stock has a fifty day simple moving average of $103.43 and a 200 day simple moving average of $96.53. The stock has a market cap of $6.29 billion, a P/E ratio of 14.97 and a beta of 0.51.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. B. Riley increased their target price on Lantheus from $105.00 to $146.00 and gave the company a "buy" rating in a report on Thursday, July 25th. Truist Financial reissued a "buy" rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. StockNews.com lowered Lantheus from a "buy" rating to a "hold" rating in a report on Thursday. JMP Securities dropped their target price on Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a report on Thursday, November 7th. Finally, Redburn Atlantic assumed coverage on Lantheus in a report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 target price on the stock. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $122.50.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.